Tami Annable
Impact in
- Oncology top 5%
- Drug Transport and Resistance Mechanisms
- Cancer Treatment and Pharmacology
- Toxicology top 5%
Papers in
-
- Ubiquitin and proteasome pathways 4
- 14-3-3 protein interactions 2
- Oncology 10
- Drug Transport and Resistance Mechanisms 4
- Cancer Treatment and Pharmacology 4
- Co-authors
- Lee M. Greenberger (12 shared papers)Frank Loganzo (9 shared papers)Sridhar K. Rabindran (1 shared paper)Eric Brown (1 shared paper)Manu Smriti Singh (1 shared paper)H He (1 shared paper)Sylvia Musto (8 shared papers)Xingzhi Tan (6 shared papers)
- Journals
- Bioorganic & Medicinal Chemistry Letters (3 papers)Molecular Cancer Therapeutics (2 papers)Gastroenterology (2 papers)American Journal Of Pathology (1 paper)Biochemistry (1 paper)
- Partner nations
- United StatesChina
In The Last Decade
Tami Annable
23 papers receiving 1.1k citations
Peers
Comparison fields: 5 of 84
- Oncology 478
- Toxicology 40
- Cell Biology 180
- Cancer Research 131
- Molecular Biology 579
Countries citing papers authored by Tami Annable
This map shows the geographic impact of Tami Annable's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tami Annable with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tami Annable more than expected).
Fields of papers citing papers by Tami Annable
This network shows the impact of papers produced by Tami Annable. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tami Annable. The network helps show where Tami Annable may publish in the future.
Co-authors
The 25 scholars most cited alongside Tami Annable, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 23 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Reversal of a novel multidrug resistance mechanism in human colon carcinoma cells by fumitremorgin C. | 1998 | 272 |
| 2 | 2006 | 129 | |
| 3 | HTI-286, a synthetic analogue of the tripeptide hemiasterlin, is a potent antimicrotubule agent that circumvents P-glycoprotein-mediated resistance in vitro and in vivo. | 2003 | 116 |
| 4 | 2017 | 74 | |
| 5 | 2017 | 61 | |
| 6 | MAC-321, a novel taxane with greater efficacy than paclitaxel and docetaxel in vitro and in vivo. | 2003 | 59 |
| 7 | 2004 | 58 | |
| 8 | 2005 | 56 | |
| 9 | A new antiestrogen, 2-(4-hydroxy-phenyl)-3-methyl-1-[4-(2-piperidin-1-yl-ethoxy)-benzyl]-1H-indol-5-ol hydrochloride (ERA-923), inhibits the growth of tamoxifen-sensitive and -resistant tumors and is devoid of uterotropic effects in mice and rats. | 2001 | 41 |
| 10 | Cells resistant to HTI-286 do not overexpress P-glycoprotein but have reduced drug accumulation and a point mutation in alpha-tubulin. | 2004 | 33 |
| 11 | 2004 | 32 | |
| 12 | 2006 | 31 | |
| 13 | 2018 | 29 | |
| 14 | 2015 | 25 | |
| 15 | P-glycoprotein mediates profound resistance to bisantrene. | 1994 | 24 |
| 16 | 2004 | 23 | |
| 17 | 2008 | 21 | |
| 18 | alpha-(3,4-dimethyoxyphenyl)-3,4-dihydro-6,7-dimethoxy-alpha- [(4-methylphenyl)thio]-2(1H)-isoquinolineheptanenitrile (CL 329,753): a novel chemosensitizing agent for P-glycoprotein-mediated resistance with improved biological properties compared with verapamil and cyclosporine A. | 1996 | 8 |
| 19 | 2014 | 8 | |
| 20 | 2008 | 7 |
About Tami Annable
Tami Annable is a scholar working on Molecular Biology, Oncology, Cell Biology, Hepatology and Surgery, having authored 23 papers that have together received 1.1k indexed citations. Recurring topics across this work include Microtubule and mitosis dynamics (6 papers), Ubiquitin and proteasome pathways (4 papers), Liver physiology and pathology (4 papers), Drug Transport and Resistance Mechanisms (4 papers), Cancer Treatment and Pharmacology (4 papers), Liver Disease Diagnosis and Treatment (3 papers), Estrogen and related hormone effects (3 papers) and 14-3-3 protein interactions (2 papers). The work is most often cited by research in Oncology (478 citations), Toxicology (40 citations), Cell Biology (180 citations), Cancer Research (131 citations) and Molecular Biology (579 citations). Tami Annable has collaborated with scholars based in United States and China. Frequent co-authors include Lee M. Greenberger, Frank Loganzo, Sridhar K. Rabindran, Eric Brown, Manu Smriti Singh, H He, Sylvia Musto, Xingzhi Tan, Malathi Hari and Tito Fojo. Their work appears in journals such as Bioorganic & Medicinal Chemistry Letters, Molecular Cancer Therapeutics, Gastroenterology, American Journal Of Pathology and Biochemistry.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.